Pioglitazone Stimulates Apolipoprotein A-I Production Without Affecting HDL Removal in HepG2 Cells
Authors:
- 1 November 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 27 (11) , 2428-2434
Abstract
Objective— Pioglitazone, an antihyperglycemic drug, increases plasma high-density lipoprotein (HDL)-cholesterol in patients with type 2 diabetes. The mechanisms by which pioglitazone regulate HDL levels are not clear. This study examined the effect of pioglitazone on hepatocyte apolipoprotein AI (apoA-I) and apoA-II production and HDL-protein/cholesterol ester uptake. Methods and Results— In human hepatoblastoma (HepG2) cells, pioglitazone, dose-dependently (0.5 to 10 μmol/L), increased the de novo synthesis (up to 45%), secretion (up to 44%), and mRNA expression (up to 59%) of apoA-I. Pioglitazone also increased apoA-II de novo synthesis (up to 73%) and mRNA expression (up to 129%). Pioglitazone did not affect the uptake of HDL 3 -protein or HDL 3 -cholesterol ester in HepG2 cells. The pioglitazone-induced apoA-I lipoprotein particles increased cholesterol efflux from THP-1 macrophages. The pioglitazone-induced apoA-I secretion or mRNA expression by the HepG2 cells was abrogated with the suppression of PPAR-α by small interfering RNA or a specific inhibitor of PPAR-α, MK886. Conclusions— The data indicate that pioglitazone increases HDL by stimulating the de novo hepatic synthesis of apoA-I without affecting hepatic HDL-protein or HDL-cholesterol removal. We suggest that pioglitazone-mediated hepatic activation of PPAR-α may be one of the mechanisms of action of pioglitazone to raise hepatic apoA-I and HDL.Keywords
This publication has 28 references indexed in Scilit:
- Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic SyndromeArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARα-mediated redistribution of ABCB4Journal of Lipid Research, 2004
- NFκB Regulates Plasma Apolipoprotein A-I and High Density Lipoprotein Cholesterol through Inhibition of Peroxisome Proliferator-activated Receptor αJournal of Biological Chemistry, 2003
- Clinical pharmacokinetics of pioglitazoneExperimental and Clinical Endocrinology & Diabetes, 2000
- Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled studyClinical Therapeutics, 2000
- Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by PioglitazoneBiochemical and Biophysical Research Communications, 2000
- Peroxisome proliferator–activated receptor γ ligands and atherosclerosis: ending the heartacheJournal of Clinical Investigation, 2000
- High density lipoprotein and lipoprotein oxidationCurrent Opinion in Lipidology, 1996
- Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein.Journal of Clinical Investigation, 1991
- Basic considerations in the reversal of atherosclerosis: Significance of high-density lipoprotein in stimulating reverse cholesterol transportThe American Journal of Cardiology, 1989